Unique ID issued by UMIN | UMIN000013513 |
---|---|
Receipt number | R000007653 |
Scientific Title | Phase 2 clinical trial of primary systemic therapy for primary breast cancer Sequential regimen of Nab-Paclitaxel followed by EC for HER2 negative breast cancer and concurrent regimen of Docetaxel/Carboplatin/Herceptin for HER2 positive breast cancer |
Date of disclosure of the study information | 2014/03/25 |
Last modified on | 2014/03/25 19:58:36 |
Phase 2 clinical trial of primary systemic therapy for primary breast cancer
Sequential regimen of Nab-Paclitaxel followed by EC for HER2 negative breast cancer and concurrent regimen of Docetaxel/Carboplatin/Herceptin for HER2 positive breast cancer
Phase 2 clinical trial of primary systemic therapy for breast cancer
Nab-Paclitaxel followed by EC for HER2- breast cancer and Docetaxel/Carboplatin/Herceptin for HER2+ breast cancer
Phase 2 clinical trial of primary systemic therapy for primary breast cancer
Sequential regimen of Nab-Paclitaxel followed by EC for HER2 negative breast cancer and concurrent regimen of Docetaxel/Carboplatin/Herceptin for HER2 positive breast cancer
Phase 2 clinical trial of primary systemic therapy for breast cancer
Nab-Paclitaxel followed by EC for HER2- breast cancer and Docetaxel/Carboplatin/Herceptin for HER2+ breast cancer
Japan |
Primary breast cancer
Hematology and clinical oncology | Breast surgery |
Malignancy
NO
To evaluate safety, clinicopathological outcome and prognosis after systemic primary chemotherapy for stage 2 and 3 breast cancer with 2cm and more in size.
1)HER2-negative breast cancer patients recieve sequential regimen of 4 cycles of Nanoparticle Albumin-bound paclitaxel followed by 4 cycles of epirubicin and cyclophophamide.
(2)HER2-positive breast cancer patients recieve concurrent regimen of 6cycles of Docetaxel(DOC), Carboplatin(CBDCA) and Trastuzumab.
Efficacy
Confirmatory
Pragmatic
Phase II
Rate of pathological complete response
Postsurgical histological response,
Rate of breast conservative surgery, clinical response, and adverse effect
DFS and overall survival
Exploratory study of imaing and molecular biomarkers
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Neoadjuvant chemotherapy using Nab-Paclitaxel followed by Epirubicin and Cyclophosphamide for HER2 negative primary breast cancer and Docetaxel/Carboplatin/Herceptin3 for HER2 positive breast cancer
20 | years-old | <= |
75 | years-old | >= |
Male and Female
Stage 2 and 3 primary breast cancer patients who are eligible for chemotherapy
Patients who are ineligible for chemotherapy
100
1st name | |
Middle name | |
Last name | Toshiaki Saeki |
International Medical Center, Saitama Medical University
Dept of breast oncology
1397-1 Yamane, Hidaka, Saitama, Japan
042-984-4111
syueda@saitma-med.ac.jp
1st name | |
Middle name | |
Last name | Shigeto UEDA |
International Medical Center, Saitama Medical University
Dept of breast oncology
1397-1 Yamane, Hidaka, Saitama
042-984-4111
syueda@saitma-med.ac.jp
Dept of breast oncology
Dept of breast oncology
Self funding
NO
2014 | Year | 03 | Month | 25 | Day |
Unpublished
Enrolling by invitation
2011 | Year | 10 | Month | 01 | Day |
2011 | Year | 10 | Month | 01 | Day |
2014 | Year | 03 | Month | 25 | Day |
2014 | Year | 03 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007653
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |